AstraZeneca has announced a major expansion ... spend $2bn to bolster its manufacturing capacity in states including Maryland and Texas as well as on the west coast. This would bring its total ...
CAMBRIDGE, England - AstraZeneca PLC (LSE/STO/Nasdaq ... and a next-generation biologics manufacturing facility in Maryland. Additional developments will consist of cell therapy manufacturing ...
The new investments will expand manufacturing sites in Maryland, Texas and California. But AstraZeneca shares have fallen nearly 6% this year, underperforming a near 9% rise in the wider European ...
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts A next generation manufacturing facility for biologics in ...
AstraZeneca has upgraded its annual guidance ... centre in Massachusetts and a manufacturing facility for biologics in Maryland. Soriot said the investment reflects the 'attractiveness of the ...
AstraZeneca made headlines for several reasons on Tuesday ... The investment will also support creation of a new next generation manufacturing facility, focused on biologics, in Maryland as well as ...
AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; A next generation manufacturing facility for biologics in ...
UK-based biopharmaceutical company AstraZeneca has announced a $3.5bn ... a new biologics manufacturing facility in Maryland and expand specialty manufacturing in Texas. Additionally, it will ...
The pact with Mankind Pharma, announced in March 2024, was an exclusive agreement for distribution of budesonide and ...